Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

November 09, 2026

Performance

52-Week Range 68.4% below 52-week high

151.57

152.1752W Low 479.7952W High

1 Week 11.1% below 1-week high

152.171W Low 170.491W High

Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY) traded between $152.17 and $479.79 over the past 52 weeks and last traded at $151.57, 68.4% below its 52-week high. Over the past week it ranged between $152.17 and $170.49.

Past 12 Months

-5.2%

-33.2%

-30.1%

-46.8%

-62.1%

-65.7%

1W -$8.32

1M -$75.45

3M -$65.41

6M -$133.27

YTD -$248.60

1Y -$290.13

ALNY was -65.7% over the past year, -46.8% over six months, -62.1% year to date, -5.2% in the last week.

12 Months vs Market

ALNY

-65.7%

DIA

+10.0%

SPY

+9.8%

QQQ

+7.8%

IWM

+14.7%

Over the past 12 months ALNY returned -65.7% versus DIA (Dow) +10.0%, SPY (S&P 500) +9.8%, QQQ (Nasdaq 100) +7.8% and IWM (Russell 2000) +14.7%.

Volume & Liquidity 0.70× 3-mo avg

Today 1,343,831 3-mo avg 1.9M

3.4M

2.8M

1.9M

1.8M

YTD

1.6M

1.5M

ALNY most recently traded 1,343,831 shares against a 3-month average daily volume of 1.9M.

More News

Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership

November 04, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum ↗

October 16, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth ↗

October 08, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗

September 03, 2026

Via Chartmill

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

November 04, 2026

3 Nasdaq-100 Stocks That Can Double, According to Wall Street ↗

November 04, 2026

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

November 03, 2026

Top US Stock Gainers and Losers for Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

Alnylam (ALNY) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

Alnylam Pharmaceuticals Q3 Earnings Call Highlights ↗

October 29, 2026

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

Premarket Gainers and Losers on Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

October 29, 2026

From Alnylam Pharmaceuticals

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial ↗

October 26, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

October 23, 2026

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

October 15, 2026

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

September 29, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗

September 20, 2026

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial ↗

September 19, 2026

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026